Trials / Not Yet Recruiting
Not Yet RecruitingNCT06719856
MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to construct a noninvasive approach using 68Ga-labeled bicyclic peptide radiotracer to detect the matrix metalloproteinase 14 (MMP14, MT1-MMP) expression of tumor lesions in patients with solid tumors and to identify patients benefiting from MMP14 targeting treatment.
Detailed description
Analysis plan: 1. Recruit 3-5 participants to analyze preliminary pharmacokinetic/first-in-human dose (FIH), major organ distribution, and tumor uptake information via whole-body PET/CT imaging; 2. Recruit 20-30 participants to analyze in vivo safety and tumor targeting information; 3. Recruit all participants for a final summary.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18-FDG | All study participants will undergo one 18F-FDG PET/ CT scan. |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
- First posted
- 2024-12-06
- Last updated
- 2024-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06719856. Inclusion in this directory is not an endorsement.